What difference does it make if Paul Allen is RLS or is heavily involved? There was not even a measly $25M upfront cash to MNKD. Any products coming out of the collaboration are likely many years in the future. Sure there may be some minor milestone payments, but those will likely only cover MNKD's expenses towards the collaboration. RLS must run trials, and that can take many years, those trials must be successful, and the the FDA must approve the product and then there is likely another year before MNKD see any profit at all.
Now if RLS is to take an equity stake in MNKD, or even make an offer on the whole Afrezza franchise, now that would be something potentially share price boosting and much nearer than say 4 to 8 years out.
Kevin's math seems to add up pretty well, far from useless.
Very disappointing that this was the best Matt could come up with. I now believe there was never any serious BP interest in the TS Platform. And this makes me question whether there was ever any serious BP interest in Afrezza, and thus of course I now wonder if there is now any BP interest in Afrezza.
Matt better deliver something impressive regarding Afrezza, and relatively soon, or we might see MNKD at 30 cents.
Not even a piddly $25 million. Not exactly a ringing vote of confidence.
Agreed. Just look at how many years it took to bring Afrezza to market.
I think we all understand that Al meant well, and truly believed what he said. He just apparently never really considered Sanofi would intentionally sandbag Afrezza.
Surely, MNKD is worth, in an outright buyout, well over the current MC. Some might say only $4, others $8, still others likely place MNKD's value at closer to $12, but for certain, 75 cents is a steal.
Sentiment: Strong Buy
I am totally serious here. Maybe the shorts can knock us down further, I don't know, but Afrezza is Everything Al said it would be.
In as little as a few weeks or months, JNJ or another Big Pharma could offer us say $12 for MNKD, granted that isn't the $27 buyout price George Rho was predicting back when MNKD's share price was in the vicinity of $10, but still. Or maybe Al has been in contact with one or more of those previously interested big pharma entities which lost out to Sanofi, and maybe we get a new partner announcement very shortly. I think MNKD shares are a screaming buy, even more so if the shorts knock us down to 50 cents.
The accumulated tax-loss carry alone must be over $1B by now.
Rant all you want, but achieving 'crazy-low A1Cs', like in the 5s, along with low rates of hypoglycemia, plus the added benefit of needle elimination and resulting increased compliance, spells eventual block buster to me.
Maybe to treat them all to watch the first Afrezza DTC TV Commercial. Something is up for certain.
Sentiment: Strong Buy